Search

everythinglearnresearchcommunity

for

Search:↓

Early intervention in patch-type alopecia may prevent progression to more severe forms by targeting immune pathways and preserving keratin.

A new genetic model may improve treatment and diagnosis for certain inherited skin diseases.

A new method accurately estimates clone sizes in cells without considering time.

Tyrosine kinase inhibitors show promise in treating some skin diseases but their definitive role in dermatology is still unclear.

Erlotinib causes skin inflammation through IL-1, which can be reduced by anakinra.

QLT0267 stops hair follicle cell growth and movement.

Tyrosine kinase inhibitors effectively treat cancers but often cause skin and other side effects.

Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.

Ritlecitinib may help treat alopecia areata by protecting hair follicles.

Ivarmacitinib effectively regrows hair in severe alopecia areata.

Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.

Blocking casein kinase 1 in skin cells can help melanocyte precursors move better, potentially helping with conditions like vitiligo or gray hair.

Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.

Primary care doctors need to monitor JAK and TYK-2 inhibitors carefully for skin conditions.

Janus Kinase Inhibitors are promising new treatments for various skin conditions due to their effectiveness and safety.

Hinokitiol may help treat hair loss by reducing inflammation and promoting hair growth.

TRIV-509 quickly improves skin barrier and cell health in atopic dermatitis.

JAK inhibitors may become the first approved treatment for alopecia areata if they are proven safe and effective.

Entospletinib effectively prevents eye and skin GVHD in mice.

JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.

Isoginkgetin reduces inflammation in cells by blocking NF-κB activation.

JAK inhibitors show promise for treating various skin diseases.

JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.

CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.

A KLK5 inhibitor effectively improved skin symptoms in a mouse model of Netherton Syndrome.

EGFRi/MEKi treatments cause hair follicles to lose some immune protection, leading to inflammation.

Ruxolitinib cream effectively targets and treats inflammatory skin diseases.

ISCK03 stops melanin production in human melanoma cells and lightens skin color in mice and guinea pigs.

Oral JAK inhibitors improved alopecia areata by modulating immune responses and boosting hair growth.

Integrin-linked kinase is crucial for normal skin healing.